Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
Identifieur interne : 001589 ( Ncbi/Checkpoint ); précédent : 001588; suivant : 001590Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
Auteurs : Daniel Tarsy [États-Unis] ; Ross J. BaldessariniSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antipsychotic Agents.
- drug therapy : Schizophrenia.
- epidemiology : Akathisia, Drug-Induced.
- etiology : Akathisia, Drug-Induced.
- Age Factors, Humans, Incidence, Risk, Risk Factors.
Abstract
Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.
DOI: 10.1002/mds.20823
PubMed: 16532448
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002D42
- to stream PubMed, to step Curation: 002D42
- to stream PubMed, to step Checkpoint: 002D38
- to stream Ncbi, to step Merge: 001589
- to stream Ncbi, to step Curation: 001589
Links to Exploration step
pubmed:16532448Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?</title><author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Harvard Medical School, and Beth Israel-Deaconess Medical Center, Boston, Massachusetts 02215, USA. dtarsy@bidmc.harvard.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Harvard Medical School, and Beth Israel-Deaconess Medical Center, Boston, Massachusetts 02215</wicri:regionArea><wicri:noRegion>Massachusetts 02215</wicri:noRegion></affiliation></author><author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J" last="Baldessarini">Ross J. Baldessarini</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20823</idno><idno type="RBID">pubmed:16532448</idno><idno type="pmid">16532448</idno><idno type="wicri:Area/PubMed/Corpus">002D42</idno><idno type="wicri:Area/PubMed/Curation">002D42</idno><idno type="wicri:Area/PubMed/Checkpoint">002D38</idno><idno type="wicri:Area/Ncbi/Merge">001589</idno><idno type="wicri:Area/Ncbi/Curation">001589</idno><idno type="wicri:Area/Ncbi/Checkpoint">001589</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?</title><author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Harvard Medical School, and Beth Israel-Deaconess Medical Center, Boston, Massachusetts 02215, USA. dtarsy@bidmc.harvard.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Harvard Medical School, and Beth Israel-Deaconess Medical Center, Boston, Massachusetts 02215</wicri:regionArea><wicri:noRegion>Massachusetts 02215</wicri:noRegion></affiliation></author><author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J" last="Baldessarini">Ross J. Baldessarini</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Akathisia, Drug-Induced (epidemiology)</term><term>Akathisia, Drug-Induced (etiology)</term><term>Antipsychotic Agents (adverse effects)</term><term>Humans</term><term>Incidence</term><term>Risk</term><term>Risk Factors</term><term>Schizophrenia (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Schizophrenia</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Akathisia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Akathisia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Humans</term><term>Incidence</term><term>Risk</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J" last="Baldessarini">Ross J. Baldessarini</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001589 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001589 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:16532448
|texte= Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:16532448" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |